These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38601163)

  • 81. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
    Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
    Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
    Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
    J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.
    Zuo Y; Leng G; Leng P
    Pathol Oncol Res; 2023; 29():1610899. PubMed ID: 37143472
    [No Abstract]   [Full Text] [Related]  

  • 85. Machine learning-based integration develops an immunogenic cell death-derived lncRNA signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Sun J; Guo H; Zhang S; Nie Y; Zhou S; Zeng Y; Sun Y
    Sci Rep; 2024 May; 14(1):11724. PubMed ID: 38778157
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
    Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
    Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    Zhang H; Lin J; Yahaya BH
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma.
    Song C; Pan S; Li D; Hao B; Lu Z; Lai K; Li N; Geng Q
    BMC Med Genomics; 2022 Sep; 15(1):198. PubMed ID: 36117156
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Identification and validation of novel lung adenocarcinoma subtypes and construction of prognostic models: based on cuprotosis-related genes.
    Wang G; Wang A; Wang L; Xu G; Hong X; Fang F
    BMC Pulm Med; 2023 Feb; 23(1):63. PubMed ID: 36774456
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Subclassification of lung adenocarcinoma through comprehensive multi-omics data to benefit survival outcomes.
    Wei J; Wang X; Guo H; Zhang L; Shi Y; Wang X
    Comput Biol Chem; 2024 Oct; 112():108150. PubMed ID: 39018587
    [TBL] [Abstract][Full Text] [Related]  

  • 93. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms.
    Zhang N; Zhang H; Liu Z; Dai Z; Wu W; Zhou R; Li S; Wang Z; Liang X; Wen J; Zhang X; Zhang B; Ouyang S; Zhang J; Luo P; Li X; Cheng Q
    Cell Prolif; 2023 Apr; 56(4):e13409. PubMed ID: 36822595
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
    Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
    Front Immunol; 2022; 13():992626. PubMed ID: 36311724
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 96. Identification of a novel anoikis-related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma.
    Diao X; Guo C; Li S
    Thorac Cancer; 2023 Jan; 14(3):320-330. PubMed ID: 36507553
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
    Li Z; Wang W; Wu J; Ye X
    Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis.
    Zhang S; Zeng X; Lin S; Liang M; Huang H
    J Clin Lab Anal; 2022 Feb; 36(2):e24190. PubMed ID: 34951053
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
    Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
    Front Immunol; 2022; 13():906889. PubMed ID: 35757722
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.